Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

9.910 -0.540 (-5.17%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,147,935
Open	10.13
Bid (Size)	9.860 (800)
Ask (Size)	9.910 (700)
Prev. Close	10.45
Today's Range	9.800 - 10.23
52wk Range	6.000 - 11.22
Shares Outstanding	185,583,896
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

June 29, 2026

From BioCryst Pharmaceuticals, Inc.

Via GlobeNewswire

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗

June 06, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth...

Via MarketBeat

Performance

YTD	+32.1%	+32.1%
1 Month	+9.4%	+9.4%
3 Month	+5.3%	+5.3%
6 Month	+39.8%	+39.8%
1 Year	+10.6%	+10.6%

More News

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗

May 07, 2026

Via Benzinga

BioCryst (BCRX) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗

May 06, 2026

Via Chartmill

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗

February 26, 2026

Via Chartmill

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗

December 12, 2025

Via Stocktwits

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

Via The Motley Fool

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 12, 2025

From Astria Therapeutics, Inc.

Via Business Wire

BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Via The Motley Fool

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗

November 03, 2025

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗

October 14, 2025

Via Stocktwits

BioCryst To Acquire Astria Therapeutics In $700M Deal ↗

October 14, 2025

Via Stocktwits

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

October 16, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗

October 14, 2025

Via Benzinga

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

October 14, 2025

From Astria Therapeutics, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

Via Benzinga

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗

August 04, 2025

Via Stocktwits

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth ↗

August 04, 2025

Via Chartmill

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?

BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market

What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?

The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 9.910

When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 07/13/26 04:00 PM ET

What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?

The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.84B

How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?

BioCryst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.